TBPH - Theravance Biopharma - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

TBPH is currently covered by 3 analysts with an average price target of $16.58. This is a potential upside of $6.97 (72.53%) from yesterday's end of day stock price of $9.61.

Theravance Biopharma's activity chart (see below) currently has 74 price targets and 52 ratings on display. The stock rating distribution of TBPH is 75% BUY and 25% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 35.05% with an average time for these price targets to be met of 99.25 days.

Highest price target for TBPH is $15, Lowest price target is $9, average price target is $16.58.

Most recent stock forecast was given by DOUGLAS TSAO from HC WAINWRIGHT on 16-Sep-2024. First documented stock forecast 03-Feb-2015.

Currently out of the existing stock ratings of TBPH, 9 are a BUY (75%), 3 are a HOLD (25%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$15

$5.48 (57.56%)

$15

2 months 5 days ago
(16-Sep-2024)

3/14 (21.43%)

$6.88 (84.73%)

35

Hold

$9

$-0.52 (-5.46%)

$10

3 months 15 days ago
(06-Aug-2024)

4/6 (66.67%)

$1.17 (14.94%)

96

Buy

$10

$0.48 (5.04%)

$14

3 months 15 days ago
(06-Aug-2024)

0/3 (0%)

$2.17 (27.71%)

Sell

$10

$0.48 (5.04%)

$10

2 years 3 months 27 days ago
(25-Jul-2022)

2/8 (25%)

$0.76 (8.23%)

70

Buy

$12

$2.48 (26.05%)

$10

2 years 5 months 29 days ago
(23-May-2022)

3/8 (37.5%)

$2.6 (27.66%)

85

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is TBPH (Theravance Biopharma) average time for price targets to be met?

On average it took 99.25 days on average for the stock forecasts to be realized with a an average price target met ratio 35.05

Which analyst has the current highest performing score on TBPH (Theravance Biopharma) with a proven track record?

JOSH SCHIMMER

Which analyst has the most public recommendations on TBPH (Theravance Biopharma)?

Josh Schimmer works at CANTOR FITZGERALD and has 3 price targets and 2 ratings on TBPH

Which analyst is the currently most bullish on TBPH (Theravance Biopharma)?

Louise Chen with highest potential upside - $45.48

Which analyst is the currently most reserved on TBPH (Theravance Biopharma)?

Brian Skorney with lowest potential downside - -$2.52

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?